Bevacizumab in age-related macular degeneration: a randomized controlled trial on the effect of on-demand therapy every 4 or 8 weeks
Author:
Affiliation:
1. Rotterdam Eye Hospital; Rotterdam the Netherlands
2. Rotterdam Ophthalmic Institute; Rotterdam the Netherlands
Funder
Stichting Wetenschappelijk Onderzoek Oogziekenhuis
Stichting voor Ooglijders
Publisher
Wiley
Subject
Ophthalmology,General Medicine
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1111/aos.13774/fullpdf
Reference28 articles.
1. A study comparing two protocols of treatment with intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration;Arias;Br J Ophthalmol,2008
2. Pharmacokinetics of intravitreal ranibizumab (Lucentis);Bakri;Ophthalmology,2007a
3. Pharmacokinetics of intravitreal bevacizumab (Avastin);Bakri;Ophthalmology,2007b
4. Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS Treat-and-Extend Protocol;Berg;Ophthalmology,2015
5. Ranibizumab or bevacizumab for neovascular age-related macular degeneration according to the Lucentis compared to Avastin study treat and extend protocol: 2 year result;Berg;Ophthalmology,2016
Cited by 14 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Insights into ocular therapeutics: A comprehensive review of anatomy, barriers, diseases and nanoscale formulations for targeted drug delivery;Journal of Drug Delivery Science and Technology;2024-08
2. Efficacy and safety of faricimab for neovascular age-related macular degeneration: a systematic review and network meta-analysis;BMJ Open Ophthalmology;2024-07
3. Predictors of stoppage and recurrence of choroidal neovascularization with a Treat- Extend-Stop protocol: 4-year follow-up;Journal Français d'Ophtalmologie;2023-12
4. Anti-angiogenic carbon nanovesicles loaded with bevacizumab for the treatment of age-related macular degeneration;Carbon;2023-01
5. An in vitro study on the effect of bevacizumab on endothelial cell proliferation and VEGF concentration level in patients with hereditary hemorrhagic telangiectasia;Experimental and Therapeutic Medicine;2022-07-05
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3